← Eichor
Study identifier: NCT04049279 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Migration in Total Hip Arthroplasty with a Cemented BiMobile Cup: Better Stability with More Cement?

Condition: Total Hip Arthroplasty · Osteoarthritis, Hip  ·  Sponsor: JointResearch

PhaseNA
Planned participants75
Who can joinAll sexes, 65 Years to no upper limit
Healthy volunteersNo

About this study

Objective: The main objective of this study is to compare the (early) migration of the cemented BiMobile cup at two year post-surgery between two different cup sizes after standard optimal reaming, and consequently adjusting the cement mantle into circa 2 or 4 mm, in patients with a primary cemented total hip arthroplasty (THA). Additionally, the results of the BiMobile cup will be compared to the Avantage cup, which is placed with a standard cup size, resulting in a cement mantle of approximately 2 mm. Study design: A prospective single centre blinded randomised controlled trial. Study population: All patients who meet the criteria to undergo a cemented THA.

This description comes directly from the study's public registry record.

Talk to the study team

Loes van Beers, MSc  ·  +31(0)20-5993653  ·  l.w.a.h.vanbeers@olvg.nl

Nienk Willigenburg, PhD  ·  +31(0)20-5992415  ·  n.w.willigenburg@olvg.nl

Always discuss trial participation with your own doctor first.

Locations (1)

OLVGAmsterdam, NetherlandsRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04049279